Table 2 Correlation of MDM2 immunostaining with tumor site, size, mitotic count, necrosis, tumor risk, and metastastatic status
From: The expression of MDM2 in gastrointestinal stromal tumors: immunohistochemical analysis of 35 cases
| Variables | MDM2 negative (%) | MDM2 positive (%) | P value |
|---|---|---|---|
| Tumor site: | |||
| Stomach | 11/17 (64.70%) | 6/17 (35.29%) | 0.87 |
| S. bowel | 5/9 (55.55%) | 4/9 (44.44%) | |
| Peritoneum | 3/5 (60%) | 2/5 (40%) | |
| Duodenum | 1/3 (33.33%) | 2/3 (66.66%) | |
| Colon | 1/1 (100%) | 0/1 (0%) | |
| Size (cm): | |||
| ≤ 5 | 7/8 (87.5%) | 1/8 (12.5%) | 0.08 |
| 5˂ S ≤ 10 | 7/17 (41.17%) | 10/17 (58.82%) | |
| > 10 | 7/10 (70%) | 3/10 (30%) | |
| Mitotic count/50 HPF: | |||
| ≤ 5 | 11/14 (78.57%) | 3/14 (21.42%) | 0.06 |
| > 5 | 10/21 (47.61%) | 11/21 (52.38%) | |
| Necrosis: | |||
| Absent | 18/27 (66.66%) | 9/27 (33.33%) | 0.14 |
| Present | 3/8 (37.5%) | 5/8 (62.5%) | |
| Risk: | |||
| Very low | 2/2 (100%) | 0/2 (0%) | 0.34 |
| Low | 4/5 (80%) | 1/5 (20%) | |
| Intermediate | 5/7 (71.42%) | 2/7 (28.57%) | |
| High | 10/21 (47.61%) | 11/21 (52.38%) | |
| Metastasis: | |||
| Absent | 20/26 (76.92%) | 6/26 (23.07%) | 0.001 |
| Present | 1/9 (11.11%) | 8/9 (88.88%) | |